you, Todd, our to and thank welcome call.
positive by defined latest commercially QX. reported approved signed closed financial an were X performance launched the reporting and solid as several Sage results Phase months posted today, ZULRESSO top-line iohexol across licensing program, for acquisition, late-stage Captisol few deals, past drug, many fronts. We partners progress for more The we're nine we positive we our updates, enabled
and the our with we're coming outlook is calendar up. financial doing events business The and our pleased well of portfolio momentum,
technology past that to about supporting to be operating business over what partners antibody I discovery our discovery we acquisition is and best-in-class our $XXX us bit a today we discover believe to acquisitions OmniAb. more built have So the investment. that through Three platform little in cost years technologies. a using leading three-and-a-half Ligand's million primary have talk about antibody OmniAb internal is antibodies. current want resulted
OmniAb and all technology genetically and to large has research. a animals private, partnerships is help of companies rats, public, namely sourcing assemble helped anogen very small, and Ligand chickens a large with that types modified portfolio do collective mice, their of an
Now molecule of suggests biologic Antibodies in largest of are research pharma antibody is the on a X successful research of an approval areas to investment one be commercial attractive to after drugs and industries biotech in R&D or category chemical-based today. rates proven higher from outcomes average dollars data and success. than Phase trial. FDA The marketing receive medicine small antibody the the
recently to more our we made Ligand in and wanted first followed antibody the by Initio. now burgeoning OMT, stage Crystal Ab late decided Bioscience, field. move claim in XXXX acquiring by We a
we good and for industry. to and business for very goals shareholders and today we the its evolving business are Like pleased operators believe Ligand serve are where any we what this with is the set could business how produce we
all not the are tuned acquired us OmniAb we XXXX but of This of when analysts and investors into them of the Generally platform well are. potential reminds Captisol.
not Some how did Ligand. into investors that potential it business, its fit understand or
R&D investors and more that success. it a acquisition, For and about needed following to years time few see learn commercial
initial wellness a was that later, and One was important Sage we license spa. when drug a cap Some search a called month questioned formed and has find market to the first did search its so but misguided Sage than they of Therapeutics. Ligand. business PPD The for license agreement wondered anything. are was value the like newly at that very Google less a with premise billion Sage market was to $X on last where approved investor with would poked Sage Today a the not said its and years and doing for launched amount drug is a based XX
about a will strength sales highly us. in earn-outs a $XX To-date illustrates on several the Captisol's of category, royalty acquisition, continue more not so of with Ligand ahead successful and more paid doubt obvious in revenue XX our have deal much and unqualified biggest still then of we million years for platform company. we for a business No winner. acquire big it Captisol that over over acquisition and success. years expect another Ligand, some or The the to How years identified it's additional made $XXX a in moved underlying upfront from million the an business. generated We
science, Today a We our than is with and strong and platform and portfolio believe IP, to promising defined potential. valuable is what our Captisol great by long-lived expected broad take platform be financial should of note. most OmniAb many that delivered partners, higher investors long-term and fold OmniAb has
sign gave years XXXX to would since we three-and-a-half do about At that new time we who the initial guidance into companies business license going deals $XX signed million we OmniAb XX our financial we antibody OmniAb. would five two year with agreements that with achieved the been the got in forecast has ago. had acquisition had the Much another we years in space per three forward. first We
for million Then locking $XX XXXX. better and the for million for we years XXXX, revenue revenue in business. business in two the XXXX did We did those in of much $XX
access generated contracts $XXX business. of the year, OmniAb who by entered We there will OmniAb than the to revenue are Today expect of antibodies. companies over end cumulative more XX have into million to this have
them We of today. X that got XXXX business but with first many target easily outlook time. programs an all expected the met into antibody see we partnerships in the would and in clinic than in clinical provided more was XXXX. active XX the when has at start this have most have we over we trial That Not advanced initially or Phase succeeded
would of that had estimate projected could the the we over animals were grow, ordered and or at looked to business ownership, antibody be our antibodies on the been campaigns number market with had in to try be that in the extrapolate to how to goal research XXXX. of time try many been conducted, the then Earlier number how annually
in It's to to exercise data And using of that gather use general the make assess right business a a conclusions classic they try potential. help value. substantial business platform is going analytics the imperfect portend investors and the can but of positive The the are building direction. company business any and a trends and own about the their clearly are
not frequently OmniAb field. meaningfully. is up use surprise animal our OmniChicken OmniMouse which is that species crowded a if for is and trends for a The used is less
OmniAb We assess research quality quantity plus currently derived of the campaigns. number as XX campaigns number, but worked discovery not the significant antibodies, partners are the XXX a to of matter may campaigns. much our We over of campaigns running as with estimate
success, Ultimately and regulatory drug by launch. are clinical focused followed on we commercial a approval
Our several sharing substantial share the business in a years acquisition Ligand's royalties in form ago. This lucrative our our their of value is built price the sales. has and around net is of increase successful of Captisol the on driven a success of time in from that partners model
our annual for Given IP, everything we substantial partner's royalties and Ligand. see OmniAb about technology, generating today our investments, we know
deals and of payments, strike We with mix a upfront annual and success OmniAb royalties. based milestones
our legacy of total potential X% there range course royalties based have of with of as sales payment million out milestones a one-time general describe $XXX then royalty but that over contract, royalties. and acquisition OMT. companies or today we X%. OmniAb A typical. down for under Most deals a of are not to have a the tiered of contracts on large have to We is of prior buy of a handful the the right And done most to structure buy is Ligand that
factors how market, we addressable other negotiations out in the settle deal final determine royalties. and the Besides on ultimately
the royalty drivers our on As OmniAb, revenue believe long-term be we investors build performance. around fundamental models should
a our ago, we Day months in potential for March, laid out At formula basic revenue. annual the Analyst royalty few
of per So drugs those drugs average In XX the number level average rate the the we the and estimated being in be royalty to XXXX potential approved outlined the in potentially factors. of a range three of to March, market as antibody the for in number factoring XX. sales given CStone data our GenMab, efficiency factoring far. we programs as and in partners success the partners their advancing And such are seeing what rates are received development were we we coming to so average with and that in and above appears estimate, it's from be to
based a Ligand investors. this on not inherent But development. as antibodies could dialogue we have number but in the start the than be drug see a know XXXX, in The crystal place that ball lower approved to with of do we technology and we uncertainties
drug top are drugs annually much drugs biggest Most largest for As limited and selling annual market $XX per markets. peak targeting today sales to are we $XXX billion about Humira The for of with revenue and more million at antibodies billion. the with sales $XX average drug smaller in the annual $X the drug smaller billion offered revenue.
like So around center expectations in but average evolve products revenue that antibodies it's can could development, a industry. the with that future range any one broad more per in just
time. information the assess be for vary evolve market and a per next on Big of have by facts for about our as we will and over provide we the revenue are to We not the information laying revenue dictating a potential and with the will framework time revenue will product year our dialogue what over but investors our portfolio decade. launch the out that
we key The to we high is sales But X.X% level, applicable in to other modeling a the that factor from royalty function is of X% in have rate average negotiated. average the royalty and rate tiers a an think is range reasonable.
can we revenue so best But is value than as strongly and to OmniAb onto felt acquisition not and early pleased made we time. our the we it something to did Captisol to those frame performing big feels and it say similar very we was they investors earlier over when analogies investors, that could I for internally Captisol were of we very better To with potential years to clear we this the expected. proud are it investors. business track very
focusing We business signed keep How well new attrition generally the in going we very will are transit clinical the revenue, and assess deals Again annual on progress. positive. forward?
not As mentioned still active. contracts have are all we signed
development with now. factor right attrition number or driving terminated We essentially contracts inactive have some inactive M&A. The seen terminations or is one
ARMO is been the AbbVie, the both Stemcentrx with have acquisition inactive deals Lilly, the process be have we we renewed not and will renewed. acquired now example contract the contract other was by one and recent OmniAb either. that BMS with in and not anticipate For Celgene
report on due we book total have we very to when simply a it's are in cage in signing constraints Other able to a a star. a attrition. partner and net of funding research a have our good like But those customers at change keep direction proportion figures partners numbers moved or cliff. of partners of been in Bear net new up mind small
the last the important six our given portfolio. months, Over in an there advancement our of evolution is dashboard
new data patients Now is products first there considering trial points across where promising. to the are treated data, metrics And data setting we of for substantial trial in all studies, launch. number the those new are time and starts, clinical
are XXXX. There X,XXX and one antibody the times with the in confident to or XX over just antibody estimate we're with the are own and can continue you year. we by all be exciting readout the end or we information first value Phase in market business, could and including say your XX pleased believe this over are we're We in of All OmniAb these assist X to a very Ligand ongoing Phase the the in be the business trials will assets the of completed mid-XXXX in About company. Needless roster state our analysis. XX enrolled recently patients are we'll other to metrics of or and trials pleased trials. in our will current We X by XXXX provide of and progress model, business with establishing trials.
of a Now I'll performance. Matt review to do QX Korenberg financial our to over turn
